ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Rejection"

  • 2017 American Transplant Congress

    Composite Prognostic Score Improves Clinical Benefit in Kidney Recipients Receiving Standard of Care Therapy for Antibody-Mediated Rejection.

    D. Viglietti, A. Loupy, O. Aubert, E. Pillebout, C. Legendre, D. Glotz, C. Lefaucheur.

    Paris Translational Research Center for Organ Transplantation, Paris, France

    There is a marked heterogeneity in AMR patients' prognosis after SOC treatment including plasma exchange (PE) and intravenous immunoglobulins (IVIG). We investigated whether the use…
  • 2017 American Transplant Congress

    In Clinic Systems to Address Adherence Barriers Decrease Late Allograft Rejection for Kidney Transplant Patients.

    D. Hooper, C. Varnell, Jr., K. Rich, D. Dahale, J. Huber, A. Pai, A. Modi.

    Cincinnati Children's Hospital Medical Center, Cincinnati, OH

    Background: Patient-identified barriers to taking immunosuppressive medications are associated with rejection and allograft loss in kidney transplant patients, yet interventions targeting adherence barriers are rarely…
  • 2017 American Transplant Congress

    Impact of a B-Cell Targeting Agent on Antibody Mediated Rejection and Graft' Survival in Liver Transplantation with Preformed DSAs.

    A. Del Bello,1 V. Dubois,2 J. Dumortier,3 N. Congy-Jolivet,4 N. Kamar.1

    1Nephrology and Organ Transplant Department, CHU Toulouse, Toulouse, France; 2Department of Immunology, CHU Lyon, Lyon, France; 3Gastroenterology and Liver Transplant Department, CHU Lyon, Lyon, France; 4Department of Immunology, CHU Toulouse, Toulouse, France

    Introduction The negative impact of preformed anti-HLA donor specific antibodies (DSAs) in liver transplantation is clearly established. However, the potential interest of a B-cell depleting…
  • 2017 American Transplant Congress

    Poor Prediction of Rejection and Kidney Survival by Donor-Specific-Antibodies Characterization.

    L. Couzi,1,2,3 M. Courant,1 J. Visentin,1,2,3 V. Dubois,4 S. Lepreux,1,2 G. Guidicelli,1 O. Thaunat,5,6 P. Merville,1,2,3 J.-L. Taupin.7

    1CHU de Bordeaux, Bordeaux, France; 2Université de Bordeaux, Bordeaux, France; 3UMR CNRS 5164 Immunoconcept, Bordeaux, France; 4Etablissement Français du Sang, Lyon, France; 5INSERM U1111, Lyon, France; 6CHU de Lyon, Lyon, France; 7Laboratoire d'Immunologie et Histocompatibilité, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Paris, France

    Kidney transplant recipients with DSA have a greater likelihood of developing antibody-mediated rejection (ABMR) and kidney allograft loss. The aim of this study was to…
  • 2017 American Transplant Congress

    Treatment and Outcomes of Simultaneous Acute Rejection and Polyomavirus Allograft Nephropathy.

    T. Sparkes, S. Hammad, C. Drachenberg, A. Haririan.

    University of Maryland, Baltimore, MD

    Background: Reduction of immunosuppression for polyomavirus allograft nephropathy (PVAN) is associated with risk of acute rejection (AR), and in uncommon cases both are present together…
  • 2017 American Transplant Congress

    Clinical and Molecular Significance of Microvascular Inflammation Negative Transplant Glomerulopathy.

    M. Lubetzky,1 N. Hayde,1 P. O Broin,2 Y. Bao,1 E. Akalin.1

    1Montefiore Medical Center, Bronx; 2National University of Ireland Galway University, Galaway, Ireland

    Transplant glomerulopathy (TGP) with donor specific antibodies (DSA) and microvascular inflammation (MVI) is due to chronic antibody mediated rejection (CAMR). We reported previously that intragraft…
  • 2017 American Transplant Congress

    Risk of Kidney Rejection Following Simultaneous Liver Kidney Transplantation.

    S. Shah,1 A. Suddle,1 V. Aluvihare,1 O. Shaw,3 C. Shaw,1 N. Mamode,2 C. Callaghan,2 G. Koffman,2 N. Heaton.1

    1King's College Hospital, London, United Kingdom; 2Guy's and St Thomas' Hospital, London, United Kingdom; 3Viapath, London, United Kingdom

    Introduction: Simultaneous liver kidney transplant (SLK) recipients may be at risk of antibody-mediated kidney rejection (AMR) if the pre-transplant crossmatch is positive (+CXM). Accordingly, in…
  • 2017 American Transplant Congress

    Development of an Anti-HLA Antibody-Producing Humanized Mouse Model.

    S. Yanagawa, H. Tahara, H. Ohdan.

    Hiroshima University, Hiroshima, Japan; Hiroshima University, Hiroshima, Japan; Hiroshima University, Hiroshima, Japan

    Chronic antibody-mediated rejection due to anti-human leukocyte antigen (HLA) antibodies (Abs) is an important problem in organ transplantation. The spleen has been reported to be…
  • 2017 American Transplant Congress

    Utility of Concomitant Biopsy in Simultaneous Pancreas Kidney Transplant Recipients in the Identification of Rejection of Pancreas and Kidney.

    C. Johnson, K. Johnson, B. Kaplan, M. Temkit, R. Heilman, S. Sukumaran Nair, H. Khamash, J. Huskey, G. Mour, H. Chakkera.

    Mayo Clinic Arizona, Phoenix, AZ

    Background: In simultaneous pancreas and kidney transplant (SPKTx) recipients, animal studies suggest concordant rejection rates of 88% (ref: Gruessner et al,1994). Limited information is available…
  • 2017 American Transplant Congress

    Tacrolimus Dose Variability, CYP3A5 Genotype, and Acute Rejection in African American and European American Kidney Transplant Recipients.

    S. Seibert,1 D. Schladt,2 B. Wu,3 W. Guan,3 C. Dorr,2,7 D. Berglund,1 R. Remmel,4 A. Matas,5 R. Mannon,6 A. Israni,2,7 W. Oetting,1 P. Jacobson,1 For the DeKAF Genomics Investigators.

    1Dept of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota (UMN), Mpls, MN; 2Chronic Disease Research Group, Minneapolis Medical Research Foundation, Mpls, MN; 3Division of Biostatistics, School of Public Health, UMN, Mpls, MN; 4Dept of Medicinal Chemistry, College of Pharmacy, UMN, Mpls, MN; 5Division of Transplantation, Dept of Surgery, School of Medicine, UMN, Mpls, MN; 6Dept of Nephrology, University of Alabama, Birmingham, AL; 7Dept of Nephrology, Hennepin County Medical Center, School of Medicine, UMN, Mpls, MN

    Background: Poor immunosuppression with tacrolimus (TAC) after kidney transplantation contributes to the development of toxicity and loss of efficacy. We aimed to associate intra-patient TAC…
  • « Previous Page
  • 1
  • …
  • 111
  • 112
  • 113
  • 114
  • 115
  • …
  • 172
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences